我們已在上線！進一步了解

Novavax

NVAX

市值 US$18.6億

11.26 USD

-1.56

12.17%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

11.19

-0.07

0.62%

1天

-12.17%

5天

-10.71%

1個月

20.43%

3個月

36.65%

6個月

30.32%

今年迄今

57.92%

1年

32.78%

5年

-93.23%

10年

-63.2%

關於： Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

員工： 749

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 51.2%

中性 27.9%

負面 20.9%

Novavax shareholder Shah Capital to step back from activist role

Shah Capital, one of Novavax's top shareholders, said on Friday it no longer seeks to influence ‌control of the vaccine maker after restructuring into a family office.

Novavax shareholder Shah Capital to step back from activist role

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

24/7 Wall Street

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Zacks Investment Research

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

In the most recent trading session, Novavax (NVAX) closed at $12.82, indicating a +1.26% shift from the previous trading day.

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

Zacks Investment Research

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

24/7 Wall Street

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%.

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Zacks Investment Research

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Novavax (NVAX) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Novavax (NVAX) closed at $11.27, marking a -10.31% move from the previous day.

Novavax (NVAX) Stock Sinks As Market Gains: Here's Why

Novavax Stock Falls Back: What's Going On?

Novavax Inc. (NASDAQ:NVAX) shares are pulling back Tuesday after a more than 20% surge Monday. Vaccine stocks rallied after a suspected pneumonic plague case in Russia.

Novavax Stock Falls Back: What's Going On?

24/7 Wall Street

Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low.

Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher

查看新聞排名

價格圖表採用Lightweight Charts™實作